CLINICAL STUDIES
Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol
Andrea Di Lenarda, MD*,
Gastone Sabbadini, MD ,
Luca Salvatore, MD*,
Gianfranco Sinagra, MD*,
Luisa Mestroni, MD, FACC ,
Bruno Pinamonti, MD*,
Dario Gregori, PhD ,
Fulvio Ciani, MD||,
Aureo Muzzi, MD*,
Silvio Klugmann, MD*,
Fulvio Camerini, MD* The Heart-Muscle Disease Study Group
* Department of Cardiology, Ospedale Maggiore, Trieste, Italy
Department of Internal Medicine and Geriatrics, University of Trieste, Trieste, Italy
International Center for Genetic Engineering and Biotechnologies, Area Science Park, Trieste, Italy
Department of Statistics, University of Trieste, Trieste, Italy
|| Respiratory Physiopathology Service, Ospedale Santorio, Trieste, Italy
Manuscript received September 25, 1998;
revised manuscript received January 27, 1999,
accepted February 25, 1999.
Reprint requests and correspondence: Dr. Andrea Di Lenarda, MD, Department of Cardiology, Ospedale Maggiore, Piazza Ospedale 1, 34100 Trieste, Italy
dilenar{at}uts.univ.trieste.it
OBJECTIVES
The purpose of this study was to analyze whether long-term treatment with the nonselective beta-adrenergic blocking agent carvedilol may have beneficial effects in patients with dilated cardiomyopathy (DCM), who are poor responders in terms of left ventricular (LV) function and exercise tolerance to chronic treatment with the selective beta-blocker metoprolol.
BACKGROUND
Although metoprolol has been proven to be beneficial in the majority of patients with heart failure, a subset of the remaining patients shows long-term survival without satisfactory clinical improvement.
METHODS
Thirty consecutive DCM patients with persistent LV dysfunction (ejection fraction  40%) and reduced exercise tolerance (peak oxygen consumption <25 ml/kg/min) despite chronic (>1 year) tailored treatment with metoprolol and angiotensin-converting enzyme inhibitors were enrolled in a 12-month, open-label, parallel trial and were randomized either to continue on metoprolol (n = 16, mean dosage 142 ± 44 mg/day) or to cross over to maximum tolerated dosage of carvedilol (n = 14, mean dosage 74 ± 23 mg/day).
RESULTS
At 12 months, patients on carvedilol, compared with those continuing on metoprolol, showed a decrease in LV dimensions (end-diastolic volume –8 ± 7 vs. +7 ± 6 ml/m2, p = 0.053; end-systolic volume –7 ± 5 vs. +6 ± 4 ml/m2, p = 0.047), an improvement in LV ejection fraction (+7 ± 3% vs. –1 ± 2%, p = 0.045), a reduction in ventricular ectopic beats (–12 ± 9 vs. +62 ± 50 n/h, p = 0.05) and couplets (–0.5 ± 0.4 vs. +1.5 ± 0.6 n/h, p = 0.048), no significant benefit on symptoms and quality of life and a negative effect on peak oxygen consumption (–0.6 ± 0.6 vs. +1.3 ± 0.5 ml/kg/min, p = 0.03).
CONCLUSIONS
In DCM patients who were poor responders to chronic metoprolol, carvedilol treatment was associated with favorable effects on LV systolic function and remodeling as well as on ventricular arrhythmias, whereas it had a negative effect on peak oxygen consumption.
|
Abbreviations and Acronyms
| | ACE | = angiotensin-converting enzyme | | CI | = confidence interval | | DCM | = dilated cardiomyopathy | | EDV | = end-diastolic volume | | EF | = ejection fraction | | ESV | = end-systolic volume | | LV | = left ventricular | | NYHA | = New York Heart Association | | VO2 | = volume of oxygen consumption |
|
This article has been cited by other articles:
|
|
|
|
 
M. Nishii, T. Inomata, H. Takehana, T. Naruke, T. Yanagisawa, M. Moriguchi, S. Takeda, and T. Izumi
Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure.
J. Am. Coll. Cardiol.,
June 17, 2008;
51(24):
2329 - 2335.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Woodcock, X.-J. Du, M. E. Reichelt, and R. M. Graham
Cardiac {alpha}1-adrenergic drive in pathological remodelling
Cardiovasc Res,
February 1, 2008;
77(3):
452 - 462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. M. Albert
Switching to Once-Daily Evidence-Based -Blockers in Patients With Systolic Heart Failure or Left Ventricular Dysfunction After Myocardial Infarction
Crit. Care Nurse,
December 1, 2007;
27(6):
62 - 72.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. Remme, J. G. Cleland, L. Erhardt, P. Spark, C. Torp-Pedersen, M. Metra, M. Komajda, C. Moullet, M. A. Lukas, P. Poole-Wilson, et al.
Effect of carvedilol and metoprolol on the mode of death in patients with heart failure
Eur J Heart Fail,
November 1, 2007;
9(11):
1128 - 1135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. Remme, C. Torp-Pedersen, J. G.F. Cleland, P. A. Poole-Wilson, M. Metra, M. Komajda, K. Swedberg, A. Di Lenarda, P. Spark, A. Scherhag, et al.
Carvedilol Protects Better Against Vascular Events Than Metoprolol in Heart Failure: Results From COMET
J. Am. Coll. Cardiol.,
March 6, 2007;
49(9):
963 - 971.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Nikolaidis, I. Poornima, P. Parikh, M. Magovern, Y.-T. Shen, and R. P. Shannon
The Effects of Combined Versus Selective Adrenergic Blockade on Left Ventricular and Systemic Hemodynamics, Myocardial Substrate Preference, and Regional Perfusion in Conscious Dogs With Dilated Cardiomyopathy
J. Am. Coll. Cardiol.,
May 2, 2006;
47(9):
1871 - 1881.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Metra, C. Torp-Pedersen, K. Swedberg, J. G.F. Cleland, A. Di Lenarda, M. Komajda, W. J. Remme, B. Lutiger, A. Scherhag, M. A. Lukas, et al.
Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial
Eur. Heart J.,
November 1, 2005;
26(21):
2259 - 2268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. R. Kowey
A Review of Carvedilol Arrhythmia Data in Clinical Trials
Journal of Cardiovascular Pharmacology and Therapeutics,
October 1, 2005;
10(4_suppl):
S59 - S68.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Di Lenarda, W. J. Remme, A. Charlesworth, J. G.F. Cleland, B. Lutiger, M. Metra, M. Komajda, C. Torp-Pedersen, A. Scherhag, K. Swedberg, et al.
Exchange of {beta}-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial)
Eur J Heart Fail,
June 1, 2005;
7(4):
640 - 649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. T. Yan, R. T. Yan, and P. P. Liu
Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials
Ann Intern Med,
January 18, 2005;
142(2):
132 - 145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. F. McBride and C. M. White
Critical Differences Among Beta-Adrenoreceptor Antagonists in Myocardial Failure: Debating the MERIT of COMET
J. Clin. Pharmacol.,
January 1, 2005;
45(1):
6 - 24.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Satwani, G. W. Dec, and J. Narula
{beta}-Adrenergic Blockers in Heart Failure: Review of Mechanisms of Action and Clinical Outcomes
Journal of Cardiovascular Pharmacology and Therapeutics,
October 1, 2004;
9(4):
243 - 255.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N G Bellenger, K Rajappan, S L Rahman, A Lahiri, U Raval, J Webster, G D Murray, A J S Coats, J G F Cleland, and D J Pennell
Effects of carvedilol on left ventricular remodelling in chronic stable heart failure: a cardiovascular magnetic resonance study
Heart,
July 1, 2004;
90(7):
760 - 764.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Bauman and R. L. Talbert
Pharmacodynamics of{beta}-Blockers in Heart Failure: Lessons from the Carvedilol Or Metoprolol European Trial
Journal of Cardiovascular Pharmacology and Therapeutics,
April 1, 2004;
9(2):
117 - 128.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. Pinamonti, A. Perkan, A. Di Lenarda, D. Gregori, and G. Sinagra
Dobutamine echocardiography in idiopathic dilated cardiomyopathy: clinical and prognostic implications
Eur J Heart Fail,
January 1, 2002;
4(1):
49 - 61.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Maack, T. Elter, G. Nickenig, K. LaRosee, M. Crivaro, A. Stablein, H. Wuttke, and M. Bohm
Prospective crossover comparison of carvedilol and metoprolol in patients with chronic heart failure
J. Am. Coll. Cardiol.,
October 1, 2001;
38(4):
939 - 946.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.K. Agarwal and P. Venugopalan
Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy
Eur J Heart Fail,
August 1, 2001;
3(4):
437 - 440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Stoschitzky, G. Koshucharova, R. Zweiker, R. Maier, N. Watzinger, F. M. Fruhwald, and W. Klein
Differing beta-blocking effects of carvedilol and metoprolol
Eur J Heart Fail,
June 1, 2001;
3(3):
343 - 349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Metra, R. Giubbini, S. Nodari, E. Boldi, M. G. Modena, and L. D. Cas
Differential Effects of {beta}-Blockers in Patients With Heart Failure : A Prospective, Randomized, Double-Blind Comparison of the Long-Term Effects of Metoprolol Versus Carvedilol
Circulation,
August 1, 2000;
102(5):
546 - 551.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Di Lenarda, G. Sabbadini, D. Gregori, G. Sinagra, and On behalf of the Heart Muscle Disease Study Group
Reply
J. Am. Coll. Cardiol.,
June 1, 2000;
35(7):
1993 - 1994.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Fauchier and B. Giraudeau
Beta-blockers and ventricular arrhythmias in dilated cardiomyopathy
J. Am. Coll. Cardiol.,
June 1, 2000;
35(7):
1993 - 1993.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Senzaki, N. Paolocci, Y. A. Gluzband, M. L. Lindsey, J. S. Janicki, M. T. Crow, and D. A. Kass
{beta}-Blockade Prevents Sustained Metalloproteinase Activation and Diastolic Stiffening Induced by Angiotensin II Combined With Evolving Cardiac Dysfunction
Circ. Res.,
April 14, 2000;
86(7):
807 - 815.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Carlson and K. Oberg
Clinical Pharmacology of Carvedilol
Journal of Cardiovascular Pharmacology and Therapeutics,
January 1, 1999;
4(4):
205 - 218.
[Abstract]
[PDF]
|
|
|
|
